<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FLURAZEPAM HYDROCHLORIDE- flurazepam hydrochlorideÂ capsuleÂ </strong><br>Mylan Pharmaceuticals Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use flurazepam hydrochloride capsules safely and effectively.  See full prescribing information for flurazepam hydrochloride capsules.<br>Â <br>FLURAZEPAM hydrochloride capsules, USP for oral use<br>Initial U.S. Approval: 1970</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Dosage and Administration (<a href="#ID_a73d1258-441a-4c1b-bf62-36f7e1a5c5a4">2</a>)Â Â Â Â Â 04/2014 </p>
<p class="Highlighta">Warnings and Precautions (<a href="#ID_bf504a43-1a12-4bd0-95b0-5b19f3ed6cf1">5</a>)Â Â Â Â Â 04/2014 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Flurazepam, a gamma-aminobutyric (GABA<span class="Sub">A</span>) agonist, is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> characterized by difficulty <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep, frequent nocturnal awakenings, and/or <span class="product-label-link" type="condition" conceptid="4283230" conceptname="Terminal insomnia">early morning awakenings</span>. (<a href="#ID_b4cfbb6e-2124-421a-a039-3ec8695b2351">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Use the lowest dose effective for the patient.</dd>
<dt>â€¢</dt>
<dd>Recommended initial dose is 15 mg for women and 15 mg or 30 mg for men. (<a href="#ID_3353fc48-3396-4f65-9fe0-1f446171c393">2.1</a>)</dd>
<dt>â€¢</dt>
<dd>Elderly or debilitated patients: recommended dose is 15 mg. (<a href="#ID_2bc2aa5c-de63-4535-959f-7d7e4587ba04">2.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>15 mg and 30 mg capsules. (<a href="#ID_510837cc-f41f-4b1d-ba48-684005424035">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Pregnancy (<a href="#ID_b1ad54ad-8c06-4ac8-aa0c-4f1cbf3e3606">4</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to flurazepam or other benzodiazepines. (<a href="#ID_b1ad54ad-8c06-4ac8-aa0c-4f1cbf3e3606">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>CNS depressant effects: Impaired alertness and motor coordination, including risk of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span>. Daytime impairment. Caution patients against driving and other activities requiring complete mental alertness. (<a href="#ID_dac41bdf-de33-4599-be5c-6dafbeeb7ff5">5.1</a>)</dd>
<dt>â€¢</dt>
<dd>When discontinued, benzodiazepine withdrawal syndrome can occur. (<a href="#ID_e4a52375-c0a6-438b-92a0-1e3ef4bba401">5.2</a>)</dd>
<dt>â€¢</dt>
<dd>The failure of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. (<a href="#ID_2e60700d-2bfa-4adf-9317-3b9d65dd8f16">5.3</a>)</dd>
<dt>â€¢</dt>
<dd>Severe anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported. Do not rechallenge if such reactions occur. (<a href="#ID_94b0725f-2271-409d-9c6b-ee9879f6376e">5.4</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="377535" conceptname="Sleep walking disorder">Sleep driving</span> and other complex behaviors while not fully awake: Risk increases with dose and concomitant CNS depressants and alcohol. Immediately evaluate any new onset behavioral changes. (<a href="#ID_1124aa21-d021-4c12-9aca-514f43d22b9e">5.5</a>)</dd>
<dt>â€¢</dt>
<dd>Worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidal thinking may occur: Prescribe the least number of capsules feasible to avoid <span class="product-label-link" type="condition" conceptid="4244894" conceptname="Intentional drug overdose">intentional overdose</span>. (<a href="#ID_ab63908b-3cd4-4627-a161-d6236e2cc480">5.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse reactions: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, light-headedness, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">staggering</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span>. (<a href="#ID_e433309d-56d6-492e-97f8-4bd941000c22">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or </span><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>CNS Depressants: Downward dose adjustment may be necessary due to additive effects. (<a href="#ID_9e989a41-e1b0-473e-a5a5-3f8a30a2db51">7</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Pregnancy: Based on animal data, may cause fetal harm. (<a href="#ID_a35ca4ab-352a-4bea-8ec3-f53445b44e28">8.1</a>)</dd>
</dl></div>
<div><div><div></div></div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 4/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage in Adults</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage in Elderly or Debilitated Patients</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 CNS-Depressant Effects and Daytime Impairment</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Benzodiazepine Withdrawal Syndrome</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Need to Evaluate for Co-morbid Disorders</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Severe Anaphylactic or <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal Thinking</span> and Behavior Changes</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Pediatric Use</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_b4cfbb6e-2124-421a-a039-3ec8695b2351"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Flurazepam hydrochloride capsules, USP are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> characterized by difficulty in <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep, frequent nocturnal awakenings, and/or <span class="product-label-link" type="condition" conceptid="4283230" conceptname="Terminal insomnia">early morning awakenings</span> <span class="Italics">[see <a href="#ID_6fcb2fab-1ead-479d-bed2-ec864166c8b2">Clinical Studies (14)</a>].</span></p>
<p>Since <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> is often transient and intermittent, short-term use is usually sufficient. Prolonged use of hypnotics is usually not indicated and should only be undertaken concomitantly with appropriate evaluation of the patient.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_a73d1258-441a-4c1b-bf62-36f7e1a5c5a4"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3353fc48-3396-4f65-9fe0-1f446171c393"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage in Adults</h2>
<p class="First">Use the lowest dose effective for the patient, as important adverse effects of flurazepam hydrochloride capsules are dose related.</p>
<p>The recommended initial dose is 15 mg for women and either 15 mg or 30 mg for men. The 15 mg dose can be increased to 30 mg if necessary for efficacy.</p>
<p>The recommended initial doses for women and men are different because flurazepam clearance is lower in women <span class="Italics">[see <a href="#ID_0525d9f8-6d99-4ba0-b966-b3bf65a264de">Pharmacokinetics (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2bc2aa5c-de63-4535-959f-7d7e4587ba04"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage in Elderly or Debilitated Patients</h2>
<p class="First">Elderly or debilitated patients may be especially sensitive to flurazepam. Since the risk of the development of oversedation, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and/or <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> increases substantially with larger doses in elderly or debilitated patients, it is recommended that in such patients the dosage be limited to 15 mg. <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Staggering</span> and <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> have also been reported, particularly in geriatric patients <span class="Italics">[see <a href="#ID_dac41bdf-de33-4599-be5c-6dafbeeb7ff5">Warnings and Precautions (5.1)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_510837cc-f41f-4b1d-ba48-684005424035"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Flurazepam Hydrochloride Capsules, USP are available containing either 15 mg or 30 mg of flurazepam hydrochloride, USP.</p>
<p>The 15 mg capsule is a hard-shell gelatin capsule with a white opaque cap and a powder blue opaque body filled with off-white to yellow powder. The capsule is axially printed with <span class="Bold">MYLAN</span> over <span class="Bold">4415</span> in black ink on both the cap and body.</p>
<p>The 30 mg capsule is a hard-shell gelatin capsule with a powder blue opaque cap and a powder blue opaque body filled with off-white to yellow powder. The capsule is axially printed with <span class="Bold">MYLAN</span> over <span class="Bold">4430</span> in black ink on both the cap and body.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_b1ad54ad-8c06-4ac8-aa0c-4f1cbf3e3606"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Flurazepam hydrochloride capsules are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to flurazepam or other benzodiazepines. Rare cases of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of flurazepam. Some patients have had additional symptoms such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, throat closing, or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> that suggest <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Patients who develop such reactions should not be rechallenged with flurazepam.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_bf504a43-1a12-4bd0-95b0-5b19f3ed6cf1"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_dac41bdf-de33-4599-be5c-6dafbeeb7ff5"></a><a name="section-5.1"></a><p></p>
<h2>5.1 CNS-Depressant Effects and Daytime Impairment</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, light-headedness, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">staggering</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> and <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> can occur, particularly in elderly or debilitated persons. Severe sedation, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, probably indicative of <span class="product-label-link" type="condition" conceptid="4240582" conceptname="Drug intolerance">drug intolerance</span> or overdosage, have been reported.</p>
<p>Flurazepam is a central nervous system (CNS) depressant and can impair daytime function even when used as prescribed. Prescribers should monitor for excess depressant effects, but impairment can occur in the absence of subjective symptoms, and may not be reliably detected by ordinary clinical exam (i.e., less than formal psychomotor testing). While pharmacodynamic tolerance or adaptation to some adverse depressant effects of flurazepam may develop, patients using flurazepam should be cautioned against driving or engaging in other hazardous activities or activities requiring complete mental alertness.</p>
<p>Additive effects occur with concomitant use of other CNS depressants (e.g., other benzodiazepines, opioids, tricyclic antidepressants, alcohol). Downward dose adjustment of flurazepam and concomitant CNS depressants should be considered. The potential for adverse drug interactions continues for several days following discontinuation of flurazepam, until serum levels of psychoactive metabolites decline.</p>
<p>Use of flurazepam with other sedative-hypnotics is not recommended. Alcohol generally should not be used during treatment with flurazepam. The risk of next-day psychomotor impairment is increased if flurazepam is taken with less than a full night of sleep remaining (7 to 8 hours); if higher than the recommended dose is taken; if coadministered with other CNS depressants <span class="Italics">[see <a href="#ID_a73d1258-441a-4c1b-bf62-36f7e1a5c5a4">Dosage and Administration (2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e4a52375-c0a6-438b-92a0-1e3ef4bba401"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Benzodiazepine Withdrawal Syndrome</h2>
<p class="First">Withdrawal symptoms of the barbiturate type have occurred after the discontinuation of benzodiazepines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2e60700d-2bfa-4adf-9317-3b9d65dd8f16"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Need to Evaluate for Co-morbid Disorders</h2>
<p class="First">Because <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span> may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> should be initiated only after a careful evaluation of the patient. The failure of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. Worsening of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative-hypnotic drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_94b0725f-2271-409d-9c6b-ee9879f6376e"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Severe Anaphylactic or <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First">Rare cases of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including flurazepam. Some patients have had additional symptoms such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, throat closing, or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> that suggest <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.</p>
<p>Some patients have required medical therapy in the emergency department. If <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> involves the tongue, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> after treatment with flurazepam should not be rechallenged with the drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1124aa21-d021-4c12-9aca-514f43d22b9e"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal Thinking</span> and Behavior Changes</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span> and behavior changes have been reported in patients treated with sedative-hypnotics including flurazepam. Some of these changes include decreased inhibition (e.g., <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span> and extroversion that seemed out of character), <span class="product-label-link" type="condition" conceptid="4092397" conceptname="Bizarre behavior">bizarre behavior</span>, and <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>. Visual and <span class="product-label-link" type="condition" conceptid="4164151" conceptname="Auditory hallucinations">auditory hallucinations</span> have also been reported. <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, and other neuro-<span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>, may occur.</p>
<p>Paradoxical reactions such as stimulation, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, increased <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">muscle spasticity</span>, and <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span> may occur unpredictably.</p>
<p>Complex behaviors such as "sleep-driving" (i.e., driving while not fully awake, with <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span> for the event) have been reported with use of sedative-hypnotics. These behaviors can occur with initial treatment or in patients previously tolerant of flurazepam or other sedative-hypnotics. Although these behaviors can occur with use at therapeutic doses, risk is increased by higher doses or concomitant use of alcohol or other CNS depressants. Due to risk to the patient and community, flurazepam should be discontinued if â€œsleep-drivingâ€? occurs.</p>
<p>Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with sleep-driving, patients usually do not remember these events.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ab63908b-3cd4-4627-a161-d6236e2cc480"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></h2>
<p class="First">Benzodiazepines may worsen <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Consequently, appropriate precautions (e.g., limiting the total prescription size and increased monitoring for <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>) should be considered. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_4ef2a8fa-7034-41a1-a24c-7a346e170806"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the label:</p>
<dl>
<dt>â€¢</dt>
<dd>CNS-depressant effects and next-day impairment <span class="Italics">[see <a href="#ID_dac41bdf-de33-4599-be5c-6dafbeeb7ff5">Warnings and Precautions (5.1)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd>Benzodiazepine Withdrawal Syndrome <span class="Italics">[see <a href="#ID_e4a52375-c0a6-438b-92a0-1e3ef4bba401">Warnings and Precautions (5.2)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd>Severe Anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> <span class="Italics">[see <a href="#ID_2e60700d-2bfa-4adf-9317-3b9d65dd8f16">Warnings and Precautions (5.3)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span> and behavior changes, and complex behaviors <span class="Italics">[see <a href="#ID_94b0725f-2271-409d-9c6b-ee9879f6376e">Warnings and Precautions (5.4)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd>Worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> <span class="Italics">[see <a href="#ID_1124aa21-d021-4c12-9aca-514f43d22b9e">Warnings and Precautions (5.5)</a>]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e433309d-56d6-492e-97f8-4bd941000c22"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Reported were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">gastrointestinal pain</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4294887" conceptname="Cluttering">talkativeness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pains</span>, body and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pains</span>, and genitourinary complaints. There have also been rare occurrences of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, flushes, difficulty in focusing, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">burning eyes</span>, faintness, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, bitter taste, excessive <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> and elevated <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, SGPT, total and direct bilirubin elevations, and elevated alkaline phosphatase. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_9e989a41-e1b0-473e-a5a5-3f8a30a2db51"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Benzodiazepines, including flurazepam, produce additive CNS depressant effects when co-administered with ethanol or other CNS depressants (e.g., psychotropic medications, anticonvulsants, antihistamines). Downward dose adjustment of flurazepam and/or concomitant CNS depressants may be necessary because of additive effects.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_a8f67f1e-69d0-45c2-9937-d576b7f94e22"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_a35ca4ab-352a-4bea-8ec3-f53445b44e28"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_2207b834-6de1-49e5-a785-767a0f9a5aab"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects. Pregnancy Category C</span></h3>
<p class="First">There are no adequate and well-controlled studies in pregnant women. Available human data on the risk of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> for benzodiazepines are inconclusive. There is insufficient evidence in humans to assess the effect of benzodiazepine exposure during pregnancy or neurodevelopment. Administration of benzodiazepines immediately prior to or during childbirth can result in a syndrome of <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and difficulty feeding. In addition, infants born to mothers who have taken benzodiazepines during the later stages of pregnancy can develop <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and subsequently withdrawal, during the postnatal period. Administration of flurazepam to pregnant animals did not indicate a risk for adverse effects on morphological development at clinically relevant doses; however, animal data for other benzodiazepines suggest that possibility of adverse developmental effects (including long-term effects on neurobehavioral and immunological function) following prenatal exposure. Flurazepam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1889f818-c86d-41e5-bd2d-7c7270a279ca"></a><a name="section-8.1.1.1"></a><p></p>
<h4><span class="Bold">Pregnancy Registry</span></h4>
<p class="First">To provide information regarding the effects of<span class="Italics"> in utero</span> exposure to flurazepam, physicians are advised to recommend that pregnant patients taking flurazepam enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves or their caregiver. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_eba0f4ec-a891-4b84-9545-b1d80071ba27"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_39041974-e6e8-4a88-924b-2ad7a1cce222"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Geriatric Use</h2>
<p class="First">Flurazepam may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and over-sedation in the elderly. Elderly patients generally should be started on a low dose of flurazepam and observed closely.</p>
<p>Elderly or debilitated patients may be more sensitive to benzodiazepines, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="ID_7b079d0e-80df-4f52-b8d2-2ba290fa60e3"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="ID_5274c2e7-ad91-4981-97b3-896faa736454"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">Flurazepam is classified as a Schedule IV controlled substance by federal regulation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9217446f-5dfd-42a3-a77d-2c84ab443773"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Addiction-prone individuals (e.g., history of <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug addiction</span> or <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>) should be under careful surveillance when receiving flurazepam because of increased risk of abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Benzodiazepine withdrawal symptoms can occur following discontinuation of flurazepam <span class="Italics">[see <a href="#ID_e4a52375-c0a6-438b-92a0-1e3ef4bba401">Warnings and Precautions (5.2)</a>].</span></p>
<p>Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug and/or administration of an antagonist. Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drugâ€™s effects over time. Tolerance may occur to both the desired and undesired effects of drugs and may develop at different rates for different effects.</p>
<p>Addiction is a primary, chronic, neurobiological disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, utilizing a multidisciplinary approach, but relapse is common. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_0bee25d4-6c51-4f35-bd9b-ed65a226d949"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Manifestations of flurazepam hydrochloride overdosage include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Respiration, pulse and blood pressure should be monitored as in all cases of drug overdosage. General supportive measures should be employed, along with immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> may be combated by judicious use of appropriate therapeutic agents. The value of dialysis has not been determined. If excitation occurs in patients following flurazepam hydrochloride overdosage, barbiturates should not be used. As with the management of intentional overdosage with any drug, it should be borne in mind that multiple agents may have been ingested.</p>
<p>Flumazenil, a specific benzodiazepine-receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be useful in situations when an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with a benzodiazepine is known or suspected. Prior to the administration of flumazenil, necessary measures should be instituted to secure airway, ventilation, and intravenous access. Flumazenil is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Patients treated with flumazenil should be monitored for resedation, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and other residual benzodiazepine effects for an appropriate period after treatment. The prescriber should be aware of a risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. The complete flumazenil package insert including CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS should be consulted prior to use.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_222ae96a-16b2-486a-bda1-daa3a49d0fc3"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Flurazepam hydrochloride is chemically 7-chloro-1-[2-(diethylamino)ethyl]-5-(<span class="Italics">o</span>-fluoro-phenyl)-1,3-dihydro-2<span class="Italics">H</span>-1,4-benzodiazepin-2-one dihydrochloride. It is a <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, crystalline compound, freely soluble in alcohol and very soluble in water. It has a molecular weight of 460.81 and the following structural formula:</p>
<div class="Figure">
<a name="id-1809161880"></a><img alt="Flurazepam Hydrochloride Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2f2db2f5-49d3-4d47-a08a-628df49d2120&amp;name=1d570fb4-722f-4d8b-ad15-350f185533b2-01.jpg">
</div>
<p>Each capsule for oral administration contains either 15 mg or 30 mg of flurazepam hydrochloride, USP and the following inactive ingredients: colloidal silicon dioxide, FD&amp;C Blue No. 1, FD&amp;C Red No. 3, gelatin, magnesium stearate, microcrystalline cellulose, powdered cellulose, sodium lauryl sulfate and titanium dioxide. The imprinting ink contains black iron oxide, D&amp;C Yellow No. 10 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, FD&amp;C Blue No. 2 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, propylene glycol and shellac glaze.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_c394e8c1-8033-495b-8af1-07232acb5431"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_42b4f7aa-bb9e-4266-a87a-b0f7eccb0c39"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Flurazepam, like other central nervous system agents of the 1,4-benzodiazepine class, presumably exerts its effects by binding to stereo-specific receptors at several sites within the central nervous system (CNS). The exact mechanism of action is unknown.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_0525d9f8-6d99-4ba0-b966-b3bf65a264de"></a><a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Flurazepam hydrochloride is rapidly absorbed from the gastro-intestinal tract. Flurazepam is rapidly metabolized and is excreted primarily in the urine. Following a single oral dose, peak flurazepam plasma concentrations ranging from 0.5 to 4.0 ng/mL occur at 30 to 60 minutes post-dosing. The harmonic mean apparent half-life of flurazepam is 2.3 hours. The blood level profile of flurazepam and its major metabolites was determined in man following the oral administration of 30 mg daily for 2 weeks. The N1-hydroxyethyl-flurazepam was measurable only during the early hours after a 30 mg dose and was not detectable after 24 hours. The major metabolite in blood was N1-desalkyl-flurazepam, which reached steady-state (plateau) levels after 7 to 10 days of dosing, at levels approximately 5- to 6-fold greater than the 24-hour levels observed on Day 1. The half-life of elimination of N1-desalkyl-flurazepam ranged from 47 to 100 hours. The major urinary metabolite is conjugated N1-hydroxyethyl-flurazepam which accounts for 22% to 55% of the dose. Less than 1% of the dose is excreted in the urine as N1-desalkyl-flurazepam.</p>
<p>This pharmacokinetic profile may be responsible for the clinical observation that flurazepam is increasingly effective on the second or third night of consecutive use and that for 1 or 2 nights after the drug is discontinued both sleep latency and total wake time may still be decreased.</p>
<p>The single dose pharmacokinetics of flurazepam were studied in 12 healthy geriatric subjects (aged 61 to 85 years). The mean elimination half-life of desalkyl-flurazepam was longer in elderly male subjects (160 hours) compared with younger male subjects (74 hours), while mean elimination half-life was similar in geriatric female subjects (120 hours) and younger female subjects (90 hours). After multiple dosing, mean steady-state plasma levels of desalkyl-flurazepam were higher in elderly male subjects (81 ng/mL) compared with younger male subjects (53 ng/mL), while values were similar between elderly female subjects (85 ng/mL) and younger female subjects (86 ng/mL). The mean washout half-life of desalkyl-flurazepam was longer in elderly male and female subjects (126 and 158 hours, respectively) compared with younger male and female subjects (111 and 113 hours, respectively).<span class="Sup">1</span></p>
<p><span class="Sup">1</span> Greenblatt DJ, Divoll M, Hammatz JS, MacLauglin DS, Shader RI: Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther 30:475â€“486, 1981.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_d33c9a0c-5c74-47d4-b84b-782a53f4048c"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></p>
<p>Studies to assess the genotoxic or carcinogenic potential of flurazepam or the effects of flurazepam on fertility have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_6fcb2fab-1ead-479d-bed2-ec864166c8b2"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Sleep laboratory studies have objectively determined that flurazepam hydrochloride capsules are effective for at least 28 consecutive nights of drug administration.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_9beb49c2-1228-4260-b33b-46afaa26ae16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Flurazepam Hydrochloride Capsules, USP are available containing either 15 mg or 30 mg of flurazepam hydrochloride, USP.</p>
<p>The 15 mg capsule is a hard-shell gelatin capsule with a white opaque cap and a powder blue opaque body filled with off-white to yellow powder. The capsule is axially printed with <span class="Bold">MYLAN</span> over <span class="Bold">4415</span> in black ink on both the cap and body. They are available as follows:</p>
<p>NDC 0378-4415-01<br>bottles of 100 capsules</p>
<p>The 30 mg capsule is a hard-shell gelatin capsule with a powder blue opaque cap and a powder blue opaque body filled with off-white to yellow powder. The capsule is axially printed with <span class="Bold">MYLAN</span> over <span class="Bold">4430</span> in black ink on both the cap and body. They are available as follows:</p>
<p>NDC 0378-4430-01<br>bottles of 100 capsules</p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p><span class="Bold">PHARMACIST:</span> Dispense a Medication Guide with each prescription.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_2ec758c7-2807-4125-8736-3d35c2b6e9c3"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-approved patient labeling (<a href="#ID_c08708be-314d-4840-88e2-7ff524c7a320">Medication Guide</a>).</span></p>
<p>Inform patients about the benefits and risks of flurazepam, stressing the importance of use as directed. Assist patients in understanding the Medication Guide and instruct them to read it with each prescription refill.</p>
<p><span class="Bold">CNS Depressant Effects and Next-Day Impairment</span></p>
<p>Tell patients that flurazepam can cause next-day impairment, even in the absence of symptoms. Caution patients against driving or engaging in other hazardous activities or activities requiring complete mental alertness when using flurazepam. Tell patients that daytime impairment may persist for several days following discontinuation of flurazepam.</p>
<p><span class="Bold">Withdrawal</span></p>
<p>Instruct patients to contact you before stopping or decreasing the dose of flurazepam, because withdrawal symptoms can occur.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal Thinking</span> and Behavior Change</span></p>
<p>Instruct patients that sedative hypnotics can cause <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span> and behavior change, including â€œsleepdrivingâ€? and other complex behaviors while not being fully awake (preparing and eating food, making phone calls, or having sex). Tell patients to call you immediately if they develop any of these symptoms.</p>
<p><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span></p>
<p>Inform patients that severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> can occur from flurazepam. Describe the signs/symptoms of these reactions and advise patients to seek medical attention immediately if these occur.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span></span></p>
<p>Tell patients that flurazepam can worsen <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and to immediately report any suicidal thoughts.</p>
<p><span class="Bold">Alcohol and Other Drugs</span></p>
<p>Ask patients about alcohol consumption, medicines they are taking now, and drugs they may be taking without a prescription. Advise patients that alcohol generally should not be used during treatment with flurazepam.</p>
<p><span class="Bold">Pregnancy</span></p>
<p>Instruct patients to inform you if they are nursing or pregnant, or may become pregnant while taking flurazepam. If a woman becomes pregnant while taking flurazepam, she should discontinue use immediately.</p>
<p><span class="Bold">Tolerance, Abuse, and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></span></p>
<p>Tell patients not to increase the dose of flurazepam on their own, and to inform you if they believe the drug â€œdoes not workâ€?.</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_c08708be-314d-4840-88e2-7ff524c7a320"></a><a name="section-17"></a><p></p>
<h1>Â Â Â </h1>
<p class="First"><span class="Bold">MEDICATION GUIDE</span><br><span class="Bold">FLURAZEPAM HYDROCHLORIDE CAPSULES, USP </span><br><span class="Bold">(flur az' e pam hye" droe klor' ide)</span><br><span class="Bold">15 mg and 30 mg</span></p>
<p>Read this before you take flurazepam hydrochloride capsules and when you get a refill. There may be new information.</p>
<p><span class="Bold">What should I know about flurazepam hydrochloride capsules?</span></p>
<dl>
<dt>â€¢</dt>
<dd>You might be <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> during the day</dd>
<dt>â€¢</dt>
<dd>You might not think clearly</dd>
<dt>â€¢</dt>
<dd>You might act strange, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span>, or upset</dd>
</dl>
<p>You might not realize these things are happening to you. You shouldnâ€™t drive or do things that need clear thinking when using flurazepam hydrochloride capsules.</p>
<dl>
<dt>â€¢</dt>
<dd>You might â€˜sleep walkâ€™ or do something else when you are asleep like eat, talk, have sex, or drive a car.</dd>
</dl>
<p><span class="Bold">Call your doctor right away if this happens.</span></p>
<p><span class="Bold">It is important to take flurazepam hydrochloride capsules exactly as prescribed. Taking too much flurazepam hydrochloride capsules or using other drugs with flurazepam hydrochloride capsules can cause side effects.</span></p>
<p><span class="Bold">What are flurazepam hydrochloride capsules?</span></p>
<p>Flurazepam hydrochloride capsules can help you sleep if you have trouble sleeping. This problem is called <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<p><span class="Bold">You can become addicted to flurazepam hydrochloride capsules.</span></p>
<p>Tell your doctor if you have ever been addicted to drugs or alcohol.</p>
<p>If youâ€™ve been using a lot of flurazepam hydrochloride capsules, talk to your doctor before stopping, because drug withdrawal symptoms like shakes and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> can happen.</p>
<p>Selling or giving away flurazepam hydrochloride capsules may harm others, and is against the law.</p>
<p><span class="Bold">Donâ€™t take flurazepam hydrochloride capsules if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>are allergic to it, or drugs like it</dd>
<dt>â€¢</dt>
<dd>are pregnant or might get pregnant</dd>
</dl>
<p>Talk to your doctor about your allergies, or if a medicine ever made your face swell or made it hard for you to breathe.</p>
<p><span class="Bold">How should I take flurazepam hydrochloride capsules?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Take only one capsule</dd>
<dt>â€¢</dt>
<dd>Take flurazepam hydrochloride capsules right as you get into bed.</dd>
<dt>â€¢</dt>
<dd>Only take flurazepam hydrochloride capsules if you can get a full nightâ€™s sleep.</dd>
</dl>
<p>If you take too much flurazepam hydrochloride capsules or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, get emergency treatment.</p>
<p><span class="Bold">Call your doctor if your <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> doesnâ€™t get better or you have side effects that <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you.</span></p>
<p>Common side effects of flurazepam hydrochloride capsules include:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></dd>
<dt>â€¢</dt>
<dd>light-headedness</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">staggering</span> and <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span></dd>
<dt>â€¢</dt>
<dd>you might have a harder time sleeping or feel sick if you stop taking flurazepam hydrochloride capsules for a few days.</dd>
</dl>
<p><span class="Bold">How should I store flurazepam hydrochloride capsules?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store at room temperature 20Â° to 25Â°C (68Â° to 77Â°F).</dd>
<dt>â€¢</dt>
<dd>Store away from light.</dd>
<dt>â€¢</dt>
<dd><span class="Bold">Flurazepam hydrochloride capsules are not for children. Keep flurazepam hydrochloride capsules and all medicines out of the reach of children.</span></dd>
</dl>
<p><span class="Bold">General Information about flurazepam hydrochloride capsules</span></p>
<dl>
<dt>â€¢</dt>
<dd>Medicines are sometimes prescribed for reasons not mentioned in a Medication Guide.</dd>
<dt>â€¢</dt>
<dd>Do not use flurazepam hydrochloride capsules for a problem for which it was not prescribed.</dd>
</dl>
<p>Keep a list of your medicines and supplements with you to show your doctor and pharmacist each time you get a new medicine.</p>
<p>If you would like more information about flurazepam hydrochloride capsules, talk with your doctor. You can ask your doctor or pharmacist for information about flurazepam hydrochloride capsules that was written for healthcare professionals.</p>
<p><span class="Bold">What are the ingredients in flurazepam hydrochloride capsules, USP?</span></p>
<p>Active Ingredient: flurazepam hydrochloride, USP</p>
<p>Inactive Ingredients: colloidal silicon dioxide, FD&amp;C Blue No. 1, FD&amp;C Red No. 3, gelatin, magnesium stearate, microcrystalline cellulose, powdered cellulose, sodium lauryl sulfate and titanium dioxide. The imprinting ink contains black iron oxide, D&amp;C Yellow No. 10 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, FD&amp;C Blue No. 2 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, propylene glycol and shellac glaze.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>For more information, call Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX).</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV  26505 U.S.A.</p>
<p>REVISED JANUARY 2015<br>FLZ:R19m</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_9bf9a61a-5966-44c1-89fb-eb92821e9eda"></a><a name="section-18"></a><p></p>
<h1>Â Â Â Â Â </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL â€“ 15 mg</span></p>
<p><span class="Bold">NDC 0378-4415-01</span></p>
<p><span class="Bold">Flurazepam</span><br><span class="Bold">Hydrochloride</span><br><span class="Bold">Capsules, USP<br>CIV</span><br><span class="Bold">15 mg</span></p>
<p><span class="Bold">PHARMACIST: Dispense the accompanying</span><br><span class="Bold">Medication Guide to each patient.</span></p>
<p><span class="Bold">Rx only 100 Capsules</span></p>
<p>Each capsule contains:<br>Flurazepam<br>hydrochloride, USP 15 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F ).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p><span class="Bold">Usual Adult Dosage: </span>See<br>accompanying prescribing<br>information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM4415A10</span></p>
<div class="Figure">
<a name="id95686961"></a><img alt="Flurazepam Hydrochloride Capsules 15  mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2f2db2f5-49d3-4d47-a08a-628df49d2120&amp;name=1d570fb4-722f-4d8b-ad15-350f185533b2-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_62eaec75-bd98-4872-8e1f-ee52275fc8da"></a><a name="section-19"></a><p></p>
<h1>Â Â Â Â Â </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL â€“ 30 mg</span></p>
<p><span class="Bold">NDC 0378-4430-01</span></p>
<p><span class="Bold">Flurazepam</span><br><span class="Bold">Hydrochloride</span><br><span class="Bold">Capsules, USP</span><br></p>
<p><span class="Bold">CIV</span></p>
<p><br><span class="Bold">30 mg</span></p>
<p><span class="Bold">PHARMACIST: Dispense the accompanying</span><br><span class="Bold">Medication Guide to each patient.</span></p>
<p><span class="Bold">Rx only 100 Capsules</span></p>
<p>Each capsule contains:<br>Flurazepam<br>hydrochloride, USP 30 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F ).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p><span class="Bold">Usual Adult Dosage: </span>See<br>accompanying prescribing<br>information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM4430A10</span></p>
<div class="Figure">
<a name="id1846122627"></a><img alt="Flurazepam Hydrochloride Capsules 30  mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2f2db2f5-49d3-4d47-a08a-628df49d2120&amp;name=1d570fb4-722f-4d8b-ad15-350f185533b2-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FLURAZEPAM HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">flurazepam hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-4415</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIVÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLURAZEPAM HYDROCHLORIDE</strong> (FLURAZEPAM) </td>
<td class="formItem">FLURAZEPAM HYDROCHLORIDE</td>
<td class="formItem">15Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POWDERED CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white opaque) ,Â BLUE (powder blue opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYLAN;4415</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-4415-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070345</td>
<td class="formItem">11/27/1985</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FLURAZEPAM HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">flurazepam hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-4430</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIVÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLURAZEPAM HYDROCHLORIDE</strong> (FLURAZEPAM) </td>
<td class="formItem">FLURAZEPAM HYDROCHLORIDE</td>
<td class="formItem">30Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POWDERED CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (powder blue opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYLAN;4430</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-4430-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070345</td>
<td class="formItem">11/27/1985</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Mylan Pharmaceuticals Inc.
							(059295980)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8aa3091d-4769-43bd-bb11-9133abfbc4ac</div>
<div>Set id: 2f2db2f5-49d3-4d47-a08a-628df49d2120</div>
<div>Version: 8</div>
<div>Effective Time: 20150121</div>
</div>
</div>Â <div class="DistributorName">Mylan Pharmaceuticals Inc.</div></p>
</body></html>
